안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
• 5분 읽기
• 2025년 11월 8일 게시
The Great Weight-Loss Windfall: A Sober Look at Pharma's Next Big Thing
Let’s be honest, when a government body, particularly an American one, makes a swift and decisive move, it’s usually a sign to pay attention. For decades, Medicare, the colossal US state health insurer, stubbornly refused to pay for weight-loss drugs. They were seen as a vanity project, a lifestyle choice. Now, in a complete reversal, they’ve opened the public purse. To me, this isn’t just a healthcare story, it’s a flashing neon sign for any investor with a pulse.
When the starting gun fires, it pays to back the favourites. In this race, the thoroughbreds are undoubtedly Eli Lilly and Novo Nordisk. These two giants have effectively cornered the market with their GLP-1 drugs, you know them as Ozempic, Wegovy, and Mounjaro. They’ve already built the factories, navigated the regulatory mazes, and established brands that are now household names. With Medicare now footing the bill for millions of potential new customers, the primary barrier to entry, a price tag of over a thousand pounds a month, has simply vanished. This isn't about creating a market, it's about unlocking a colossal one that was already there, just waiting. The demand is practically insatiable, and these two firms are holding the only taps.
Of course, no duopoly lasts forever. The current crop of wonder drugs has an Achilles' heel, they require weekly injections. It’s a bit of a faff, isn't it? This creates a tantalising opportunity for smaller, nimbler biotech firms. The holy grail is a simple pill that does the same job. Companies are pouring fortunes into clinical trials for oral alternatives, and if one of them cracks the code, they could disrupt the entire landscape. Investing in these innovators is certainly a riskier proposition. It’s a bet on the science paying off. But the potential reward, should they succeed, is astronomical. It’s the classic David versus Goliath story, played out in laboratories and boardrooms.
I find that investors often get mesmerised by the shiny, headline-grabbing drug makers. They forget that for every blockbuster drug, there’s a vast, unseen network required to get it from the factory to the patient. Think of firms like McKesson or Cardinal Health as the plumbers of the pharmaceutical world. They handle the logistics, and their fees are tied to volume and value. More expensive drugs moving in greater numbers means more profit for them. Then you have the high street chemists like CVS and Walgreens. They are the final, crucial link in the chain. This surge in prescriptions is a straightforward volume game for them, and it’s a game they are perfectly positioned to win without taking on any of the research and development risk.
Now, before you rush off and remortgage the house, a dose of reality is in order. Government intervention is a double-edged sword. Yes, Medicare is creating the market, but it is also negotiating prices quite aggressively. This could put a cap on the frankly eye-watering profit margins these companies have enjoyed. To me, the whole situation is a fascinating case study in the Obesity Drug Pricing | Pharma Investment Theme, where government policy directly creates and shapes a market. There are also manufacturing hurdles to consider, as shortages have already shown. And let’s not forget the patent cliff, that inevitable moment when generic competition arrives. This isn't a risk-free bet, it's a calculated one based on a monumental policy shift.
전체 바스켓 보기:Obesity Drug Pricing | Pharma Investment Theme
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기